Eisai Co., Ltd. (ESAIY)
OTCMKTS
· Delayed Price · Currency is USD
7.12
+0.04 (0.56%)
Apr 24, 2025, 3:58 PM EDT
Eisai Revenue
Eisai had revenue of 216.14B JPY in the quarter ending December 31, 2024, with 21.63% growth. This brings the company's revenue in the last twelve months to 791.66B, up 5.63% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
791.66B JPY
Revenue Growth
+5.63%
P/S Ratio
1.60
Revenue / Employee
71.53M JPY
Employees
11,067
Market Cap
8.03B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Eisai News
- 9 days ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 7 weeks ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 2 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 2 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters
- 3 months ago - US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug - Reuters
- 3 months ago - Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial - Reuters
- 4 months ago - Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases - Business Wire